Affinage

Showing KCNA3KV1.3 is a alias.

KCNA3

Potassium voltage-gated channel subfamily A member 3 · UniProt P22001

Length
575 aa
Mass
63.8 kDa
Annotated
2026-06-10
100 papers in source corpus 40 papers cited in narrative 40 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 9/9 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

KCNA3 encodes Kv1.3, a voltage-gated potassium channel that sets membrane potential and controls Ca2+-dependent activation, cytokine production, and proliferation in T lymphocytes, microglia, and other cell types (PMID:10607427, PMID:17088564). In activated effector memory T cells the channel traffics to the immunological synapse, where its residence regulates the duration of Ca2+ influx during antigen presentation (PMID:17088564, PMID:19959227). Beyond canonical ion conduction, Kv1.3 drives proliferation through a non-conducting, voltage-sensor-dependent mechanism: a poreless channel retains pro-proliferative activity, voltage-dependent conformational change triggers MEK-ERK1/2 phosphorylation of C-terminal Tyr-447, and this same signaling axis increases mitochondrial oxidative phosphorylation and ROS to promote cell-cycle progression (PMID:22383699, PMID:26655221, PMID:33828089). Kv1.3 also resides in the inner mitochondrial membrane, where Bax binds and inhibits the channel—via a conserved lysine analogous to that in Kv1.3-blocking toxins—to trigger hyperpolarization, ROS, cytochrome c release, and apoptosis (PMID:18818304, PMID:20114030). Cryo-EM of human Kv1.3 with nanobody and antibody-toxin blockers has defined two distinct pore-inhibition modes, including toxin insertion of a critical lysine into the pore (PMID:35788586). Channel activity, surface density, and subcellular distribution are extensively regulated: PKC and PKA phosphorylation tune gating (PMID:9070466, PMID:9277360); receptor tyrosine kinases (EGFR, insulin receptor) and ERK1/2-dependent phosphorylation drive clathrin-mediated endocytosis and lysosomal degradation, with Nedd4-2 ubiquitination and PSD-95/raft recruitment opposing this turnover (PMID:9348331, PMID:26542799, PMID:28186199); N-glycosylation and a caveolin-1-binding N-terminal domain promote surface localization, the latter also gating mitochondrial accumulation (PMID:22613618, PMID:26931497, PMID:34196606). The channel assembles by random tetramerization and forms heterotetramers with Kv1.5 and is inhibited by the KCNE4 accessory subunit, which masks a C-terminal surface-targeting motif to retain Kv1.3 in the ER (PMID:8868051, PMID:17038323, PMID:19773357, PMID:27802162). Kcna3 transcription is repressed by cereblon binding to promoter-adjacent DNA elements and activated by Fyn and Sp1, linking channel abundance to T cell and microglial inflammatory output (PMID:27439875, PMID:32597830, PMID:25829491). Genetic deletion in mice alters olfactory bulb physiology and lowers olfactory detection thresholds, while in immune cells loss is compensated by an induced chloride current (PMID:14766178, PMID:12878608).

Mechanistic history

Synthesis pass · year-by-year structured walk · 25 steps
  1. 1996 Medium

    Established how Kv1.3 channels assemble, showing tetramer formation is a random subunit process amenable to dominant-negative suppression.

    Evidence Kinetic analysis of heterotetramer C-type inactivation and dominant-negative truncation constructs in Jurkat cells

    PMID:8868051

    Open questions at the time
    • Does not define ER biogenesis steps
    • No structural basis for subunit interface
  2. 1997 Medium

    Resolved how PKC and PKA phosphorylation tune native Kv1.3 gating, identifying PKC as the dominant regulatory switch in T cells.

    Evidence Whole-cell patch clamp of primary human T lymphocytes with PKC/PKA activators, inhibitors, and phosphatase inhibitors

    PMID:9070466 PMID:9277360

    Open questions at the time
    • Phosphorylation sites not mapped
    • Mechanistic link between phosphorylation and gating shift not defined
  3. 1997 High

    Showed receptor tyrosine kinases directly modulate Kv1.3, distinguishing EGFR (Y479-dependent current suppression, faster inactivation) from insulin receptor regulation.

    Evidence Whole-cell patch clamp in HEK293 co-expression with Y479F mutagenesis and kinase inhibitors

    PMID:9348331

    Open questions at the time
    • Downstream trafficking consequences not addressed at this stage
    • Does not establish endogenous receptor coupling
  4. 1999 Medium

    Demonstrated that Kv1.3 controls Ca2+-dependent T cell activation, establishing it as a target for immunosuppression.

    Evidence Electrophysiology, Ca2+ flux, IL-2 ELISA, proliferation assays, and in vivo hypersensitivity with the blocker correolide

    PMID:10607427

    Open questions at the time
    • Does not distinguish conducting from non-conducting roles
    • No molecular signaling intermediates
  5. 1999 Medium

    Linked a Kv1.5-to-Kv1.3 channel switch with microglial proliferation, tying Kv1.3 surface expression to a proliferative state.

    Evidence Tissue printing, patch clamp, immunocytochemistry, and channel blockers in hippocampal microglia

    PMID:10594052

    Open questions at the time
    • Mechanism of channel switch not defined
    • Correlative rather than causal at molecular level
  6. 2000 High

    Defined the cooperative ER topogenesis of Kv1.3, identifying which transmembrane segments integrate independently and the T1-domain control of S1.

    Evidence Cell-free translation/translocation, protease protection, glycosylation insertion, and carbonate extraction

    PMID:10651649

    Open questions at the time
    • Does not address folding into functional tetramer
    • No chaperone involvement defined
  7. 2003 Medium

    Identified KCNE4 as a selective inhibitory beta-subunit of Kv1.3 and characterized choroid plexus Kv1.1/Kv1.3 conductance and its 5-HT/PKC regulation.

    Evidence Heterologous expression with patch clamp; selective blockers and receptor/PKC pharmacology in choroid plexus epithelium

    PMID:12944270 PMID:14602579

    Open questions at the time
    • Molecular basis of KCNE4 selectivity not defined
    • Physiological role of choroid plexus current unresolved
  8. 2003 High

    Showed Kv1.3 is dispensable for immune development in vivo due to a compensatory chloride current in knockout thymocytes.

    Evidence Kv1.3-/- mice with patch clamp, flow cytometry, and proliferation assays

    PMID:12878608

    Open questions at the time
    • Identity of compensatory chloride conductance unknown
    • Does not exclude functional roles maskable by compensation
  9. 2004 High

    Revealed an unexpected neuronal role through knockout phenotyping, with Kv1.3 shaping olfactory bulb physiology and olfactory sensitivity.

    Evidence Gene-targeted KO mice with patch clamp, behavioral olfaction tests, and immunohistochemistry

    PMID:14766178

    Open questions at the time
    • Mechanism linking channel to glomerular anatomy unclear
    • Scaffolding-protein upregulation not mechanistically dissected
  10. 2006 High

    Established Kv1.3/Kv1.5 heterotetramers as physiologically tunable channels in macrophages, with TNF-alpha biasing subunit composition.

    Evidence Co-IP, FRET, and patch clamp across HEK293 and Xenopus oocytes

    PMID:17038323

    Open questions at the time
    • Stoichiometry of heterotetramers not fixed
    • In vivo relevance of TNF-alpha shift not tested
  11. 2006 High

    Localized Kv1.3 to the immunological synapse with defined scaffolding partners and confirmed therapeutic relevance of blockers in effector memory T cells.

    Evidence Confocal co-localization with Kvbeta2, SAP97, ZIP, p56lck, CD4; electrophysiology and functional T cell assays across patient cohorts

    PMID:17088564

    Open questions at the time
    • Trafficking machinery to synapse not defined
    • Direct binding partners not biochemically distinguished from co-localization
  12. 2008 High

    Defined mitochondrial Kv1.3 as a direct apoptotic effector, with Bax binding and inhibiting the channel via a toxin-mimicking lysine to trigger cytochrome c release.

    Evidence siRNA, KO, mitochondria-targeted reconstitution, isolated mitochondria assays, and BaxK128E mutagenesis

    PMID:18818304

    Open questions at the time
    • Structural detail of Bax-Kv1.3 contact not resolved
    • Relationship to plasma-membrane pool not addressed
  13. 2008 Medium

    Showed Kv1.5 association rewires Kv1.3 trafficking and raft targeting, and characterized Kv1.3 in sympathetic neurons regulating norepinephrine release.

    Evidence FRET/FRAP/co-IP in macrophages; patch clamp, immunohistochemistry, and NE release assays in postganglionic sympathetic neurons

    PMID:18218624 PMID:18614767

    Open questions at the time
    • Mechanism of altered raft targeting not molecularly defined
    • Neuronal signaling consequences incompletely mapped
  14. 2009 Medium

    Mapped how KCNE4 inhibits Kv1.3 in leukocytes by ER retention and impaired raft targeting, and linked Kv1.3 synapse residence to Ca2+ signaling duration in autoimmunity.

    Evidence Co-expression patch clamp, surface/raft assays; two-photon imaging of Kv1.3 trafficking and Ca2+ in SLE versus control T cells

    PMID:19773357 PMID:19959227

    Open questions at the time
    • Cause of premature synapse exit in SLE unknown
    • KCNE4 retention motif not yet localized in this study
  15. 2010 Medium

    Extended mitochondrial Kv1.3 apoptotic function to cancer cells and implicated the channel in cell-autonomous neuronal death after axonal injury.

    Evidence Mitochondrial fractionation and recombinant Bax incubation in PC3/MCF-7; in vivo optic nerve transection with Kv1.3 siRNA and apoptosis gene readouts

    PMID:19696788 PMID:20114030

    Open questions at the time
    • Whether nuclear/mitochondrial pools drive RGC death not separated
    • Pro-apoptotic gene regulation mechanism unresolved
  16. 2012 High

    Demonstrated a pore-independent, voltage-sensor-dependent pro-proliferative function and defined N229 glycosylation as a surface-expression determinant.

    Evidence Poreless and gating-deficient mutants with proliferation assays in HEK cells; N-glycosylation mutagenesis with surface biotinylation and patch clamp

    PMID:22383699 PMID:22613618

    Open questions at the time
    • Downstream effector of voltage-sensor signaling not yet identified
    • How glycosylation alters internalization not mechanistically defined
  17. 2015 Medium

    Identified the signaling output of the non-conducting mechanism, with voltage-dependent gating driving MEK-ERK1/2 phosphorylation of C-terminal Tyr-447/Ser-459, and characterized functional nuclear Kv1.3.

    Evidence Chimeric Kv1.3-Kv1.5 channels and point mutants with MEK inhibitors and proliferation assays; nuclear fractionation, nuclear patch clamp, ChIP, and co-IP (UBF1, Sp1)

    PMID:25829491 PMID:26655221

    Open questions at the time
    • How a membrane channel signals to ERK is not structurally defined
    • Nuclear channel topology and transcriptional targets incompletely defined
  18. 2015 Medium

    Established EGFR-triggered, ERK1/2-mediated threonine phosphorylation as the critical signal driving clathrin-dependent endocytosis and lysosomal degradation of Kv1.3.

    Evidence Endocytosis assays with clathrin and ERK inhibitors and site-directed mutants (PDZ, SH3, tyrosine)

    PMID:26542799

    Open questions at the time
    • Phospho-threonine site not pinpointed
    • Adaptor linking phosphorylation to clathrin machinery unknown
  19. 2016 High

    Defined transcriptional and trafficking control nodes: cereblon represses Kcna3 via direct DNA binding, caveolin-1 targets Kv1.3 to caveolar rafts, KCNE4 masks the YMVIEE surface motif, and Kv1.3 supports M1 microglial ROS/inflammation.

    Evidence Crbn KO with ChIP and T cell/EAE assays; caveolin-binding-domain mutagenesis and raft fractionation; KCNE4 domain mapping by co-IP; microglial patch clamp with pharmacology

    PMID:26931497 PMID:27439875 PMID:27696527 PMID:27802162

    Open questions at the time
    • Cereblon DNA-binding motif structure not resolved
    • Interplay between raft targeting and degradation not integrated
  20. 2017 Medium

    Identified the degradation machinery, showing PKC-triggered Nedd4-2 ubiquitination drives Kv1.3 endocytosis and lysosomal turnover, with PSD-95 raft recruitment protecting the channel.

    Evidence Co-IP, ubiquitination assays, clathrin/lysosomal inhibitors, and flow cytometry in leukocytes

    PMID:28186199

    Open questions at the time
    • Ubiquitination sites not mapped
    • Direct Nedd4-2 recognition motif undefined
  21. 2018 Medium

    Linked caveolar Kv1.3 localization to insulin signaling in adipocytes, with caveolin-1 required for insulin-dependent channel phosphorylation.

    Evidence Caveolin-1 KO adipocytes with raft fractionation, co-IP, phosphorylation, and glucose uptake assays

    PMID:29947924

    Open questions at the time
    • Phosphorylation site and kinase not defined
    • Functional role of phospho-Kv1.3 in glucose handling unresolved
  22. 2020 Medium

    Established Fyn as a direct binding kinase regulating Kv1.3 in microglia and connected Kv1.3 to integrin-VCAM-1-driven neurotoxic glutamate release by Th17 cells.

    Evidence Proximity ligation, patch clamp, and Kv1.3-KO microglia in PD models; glutamate release and SNARE assays with Kv1.3 blockade

    PMID:31661467 PMID:32597830

    Open questions at the time
    • Fyn modification site on Kv1.3 not identified
    • How channel activity couples to vesicular release machinery unclear
  23. 2021 Medium

    Mechanistically connected the non-conducting role to bioenergetics and revealed a caveolin-1-controlled mitochondrial-versus-plasma-membrane partitioning of Kv1.3.

    Evidence Respirometry with poreless/voltage-sensor/ERK-site mutants and ROS assays; caveolin-binding-domain mutant with subcellular fractionation and survival assays

    PMID:33828089 PMID:34196606

    Open questions at the time
    • How a pore-independent channel boosts OXPHOS is not biochemically resolved
    • Quantitative balance between organelle pools not defined
  24. 2022 High

    Provided high-resolution structural mechanisms of pore inhibition and defined the unconventional TIM23/HSP70-HSP90-dependent mitochondrial import route for Kv1.3.

    Evidence Cryo-EM of Kv1.3 with nanobody and antibody-toxin blockers; mitochondrial import assays with TIM23 interaction and chaperone inhibition

    PMID:35402277 PMID:35788586

    Open questions at the time
    • Structure of native open/inactivated states without inhibitors not parsed here
    • Targeting signal directing import versus surface delivery not fully defined
  25. 2024 Medium

    Mapped the domain-resolved interactome, assigning N-terminal interactions to surface/mitochondrial trafficking and a C-terminal PDZ-binding hub to immune signaling, including functional STAT1 coupling.

    Evidence TurboID proximity labeling proteomics with domain-specific constructs and functional channel-blockade validation in microglia

    PMID:38936775

    Open questions at the time
    • Direct versus proximity-only interactions not separated
    • Mechanism of STAT1 coupling to channel activity undefined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the non-conducting voltage-sensor conformational change is physically transmitted to ERK1/2 and to mitochondrial respiration, and how surface, mitochondrial, and nuclear pools are quantitatively partitioned, remains unresolved.
  • No structural model of channel-to-kinase coupling
  • Partitioning signals between organelle pools not defined
  • Direct nuclear and mitochondrial interactors not fully validated

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0005215 transporter activity 4
Localization
GO:0005739 mitochondrion 4 GO:0005886 plasma membrane 4 GO:0005783 endoplasmic reticulum 3 GO:0005634 nucleus 1
Pathway
R-HSA-168256 Immune System 4 R-HSA-162582 Signal Transduction 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-74160 Gene expression (Transcription) 2
Complex memberships
Kv1.1/Kv1.3 choroid plexus channelKv1.3-KCNE4 channel complexKv1.3/Kv1.5 heterotetramer

Evidence

Reading pass · 40 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2022 Cryo-EM structures of human Kv1.3 alone, with a nanobody inhibitor, and with an antibody-toxin fusion blocker revealed two distinct inhibitory mechanisms: four nanobody copies bind the voltage-sensing domains and pore domain to induce an inactive pore conformation, while the antibody-toxin fusion docks its toxin domain at the extracellular mouth and inserts a critical lysine into the pore, stabilizing an active pore conformation while blocking ion permeation. Cryo-EM structure determination with functional validation Nature communications High 35788586
2008 Kv1.3 is present in the inner mitochondrial membrane of lymphocytes. Bax interacts with and functionally inhibits mitochondrial Kv1.3, triggering sequential hyperpolarization, ROS formation, cytochrome c release, and depolarization. Mutation of Bax at K128, corresponding to a conserved lysine in Kv1.3-inhibiting toxins, abrogated Bax effects on both Kv1.3 and mitochondria. Cells lacking Kv1.3 or with siRNA knockdown resisted Bax-induced apoptosis, restored by retransfection with mitochondria-targeted Kv1.3. siRNA knockdown, genetic KO, reconstitution with mitochondria-targeted Kv1.3, isolated mitochondria incubation with recombinant Bax/t-Bid, site-directed mutagenesis (BaxK128E) Proceedings of the National Academy of Sciences of the United States of America High 18818304
1997 EGF receptor and insulin receptor tyrosine kinases modulate Kv1.3 current. EGF treatment suppresses Kv1.3 current and speeds C-type inactivation via tyrosine phosphorylation; mutation of tyrosine at position 479 to phenylalanine blocks the EGF-mediated current suppression. Insulin treatment also inhibits Kv1.3 current but does not affect C-type inactivation kinetics, indicating distinct mechanisms for the two receptor tyrosine kinases. Whole-cell patch clamp in HEK293 co-expression system, site-directed mutagenesis (Y479F), tyrosine kinase inhibitor (erbstatin), receptor-blocking antibody The Journal of general physiology High 9348331
2006 Kv1.3 and Kv1.5 form functional heterotetramers in macrophages. Co-expression shifts half-activation voltage and alters pharmacological sensitivity. Both proteins co-immunoprecipitate and FRET studies confirm heteroteramer formation. TNF-α activation increases Kv1.3 without changing Kv1.5, producing a hyperpolarized shift consistent with increased Kv1.3 content. Co-immunoprecipitation, FRET, co-expression in HEK293 and Xenopus oocytes, whole-cell patch clamp, pharmacological profiling The Journal of biological chemistry High 17038323
2006 In activated effector memory T cells (TEM), Kv1.3 traffics to the immunological synapse during antigen presentation where it colocalizes with Kvβ2, SAP97, ZIP, p56(lck), and CD4. Kv1.3 inhibitors suppress Ca2+-signaling, cytokine production, and proliferation of TEM cells at pharmacologically relevant concentrations. Immunofluorescence/confocal microscopy, electrophysiology, Ca2+ signaling assays, cytokine/proliferation assays Proceedings of the National Academy of Sciences of the United States of America High 17088564
2009 KCNE4, but not KCNE2, functions as an inhibitory partner of Kv1.3 in leukocytes. KCNE4 decreases Kv1.3 current density, slows activation, accelerates inactivation, retains Kv1.3 in the ER, and impairs targeting to lipid raft microdomains, reducing cell surface channel number. Co-expression, whole-cell patch clamp, confocal co-localization, surface expression assays, lipid raft fractionation Journal of cell science High 19773357
2003 KCNE4 beta-subunit has a drastic inhibitory effect on Kv1.3 currents expressed in both Xenopus oocytes and HEK293 cells. KCNE4 does not inhibit Kv1.2, Kv1.4, Kv1.5, or Kv4.3 homomeric channels but reduces current through Kv1.1/Kv1.2 and Kv1.2/Kv1.3 heteromeric complexes. Heterologous expression in Xenopus oocytes and HEK293 cells, whole-cell patch clamp, confocal microscopy, Western blot Biophysical journal High 12944270
2016 The C-terminal domain of Kv1.3 is necessary and sufficient for interaction with KCNE4. KCNE4 retains Kv1.3 intracellularly via two independent mechanisms: masking the YMVIEE C-terminal surface targeting sequence, and an ER retention motif within KCNE4 itself. Co-immunoprecipitation, chimeric/truncation constructs, surface expression assays, confocal microscopy Journal of cell science Medium 27802162
2000 During ER biogenesis of Kv1.3, transmembrane segments S1, S2, S4, and S5 exhibit signal anchor or membrane integration activity; S3 and S6 fail to integrate independently. The N-terminal T1 domain prevents S1 from initiating translocation, making S2 the likely initial signal sequence. Multiple topogenic determinants cooperate during Kv1.3 assembly. Protease protection assays, glycosylation site insertion, carbonate extraction, cell-free translation/translocation system Biochemistry High 10651649
1997 PKC activation upregulates native Kv1.3 channel activity in human T lymphocytes, shifting voltage dependence of activation and inactivation and increasing window current ~270%. PKC inhibition reduces current. PKC-dependent phosphorylation acts as a master switch that overrides PKA-mediated upregulation. Whole-cell patch clamp in primary human T lymphocytes, pharmacological PKC activators/inhibitors, pseudosubstrate peptides, calphostin C dose-response The Journal of membrane biology Medium 9070466
1997 PKA activation increases native Kv1.3 conductance in human T lymphocytes by ~60% and shifts inactivation voltage, increasing window current. Phosphatase inhibition (okadaic acid) similarly increases conductance. PKC and PKA effects are not simply additive; PKC-dependent phosphorylation dominates regulation. Whole-cell patch clamp, pharmacological PKA activators/inhibitors, phosphatase inhibitors in primary human T lymphocytes The American journal of physiology Medium 9277360
2004 Gene-targeted deletion of Kv1.3 in mice alters potassium current kinetics in olfactory bulb mitral cells (slow inactivation, modified voltage dependence, dampened C-type inactivation), abolishes modulation by receptor tyrosine kinase activators, and increases expression of scaffolding proteins that normally regulate the channel through protein-protein interactions. KO mice have smaller, more numerous olfactory glomeruli and dramatically lower olfactory detection thresholds. Gene-targeted KO mice, whole-cell patch clamp, behavioral olfaction tests, immunohistochemistry, Western blot Neuron High 14766178
2003 Kv1.3-deficient mouse thymocytes lack voltage-dependent K+ current, but develop a ~50-fold increased chloride current as a compensatory mechanism. Despite loss of Kv1.3, no defects in lymphocyte numbers, thymocyte apoptosis, or T cell proliferation are observed in mice, likely due to this chloride current compensation. Genetic KO mice (Kv1.3-/-), whole-cell patch clamp, flow cytometry, proliferation assays The Journal of biological chemistry High 12878608
2011 KCNE2 forms functional potassium channels with KCNA3 (Kv1.3) in the choroid plexus epithelium apical membrane. Targeted Kcne2 deletion alters KCNA3 trafficking polarity, hyperpolarizes the choroid plexus membrane by ~9 mV, and increases CSF chloride concentration by 14%. Kcne2 KO mice, patch clamp, immunohistochemistry, ion-selective electrodes for CSF composition, pharmacological blockers (margatoxin) FASEB journal High 21859894
2016 Cereblon (CRBN) epigenetically represses Kcna3 (Kv1.3) transcription by directly binding conserved DNA elements adjacent to Kcna3 via a previously uncharacterized DNA-binding motif. In the absence of CRBN, Kv1.3 expression is derepressed, increasing K+ flux, Ca2+-mediated signaling, and CD4+ T cell hyperactivation. Crbn KO mice, ChIP assay, Ca2+ flux assays, cytokine production, EAE model, CD4+ T cell functional assays Proceedings of the National Academy of Sciences of the United States of America High 27439875
2012 Kv1.3 promotes cell proliferation in vascular smooth muscle cells through an ion-flux independent mechanism requiring voltage-dependent conformational change. A poreless Kv1.3 mutant retains pro-proliferative activity, but abolishing voltage-dependent gating eliminates this effect. Heterologous expression in HEK cells, poreless mutant and gating-deficient mutant channels, proliferation assays, electrophysiology Arteriosclerosis, thrombosis, and vascular biology High 22383699
2015 Kv1.3 C-terminal residues Tyr-447 and Ser-459 are required for Kv1.3-induced cell proliferation. Voltage-dependent channel gating induces MEK-ERK1/2-dependent phosphorylation of Tyr-447, providing a signaling mechanism linking channel conformational change to proliferation independently of ion conduction. Chimeric Kv1.3-Kv1.5 channels, point mutants, GFP/cherry fusion proteins, immunocytochemistry, electrophysiology, MEK inhibitors, proliferation assays in HEK293 cells The Journal of biological chemistry High 26655221
2017 PKC activation triggers ubiquitination of Kv1.3 by the E3 ubiquitin ligase Nedd4-2, leading to clathrin-mediated endocytosis and lysosomal degradation, thereby reducing surface channel expression. PSD-95 (MAGUK family) recruits Kv1.3 to lipid raft microdomains and protects it from ubiquitination and endocytosis. Adenosine stimulates PKC-mediated Kv1.3 downregulation as an immunosuppressive mechanism. Co-immunoprecipitation, ubiquitination assays, clathrin inhibitors, lysosomal pathway inhibitors, flow cytometry, confocal microscopy in leukocytes Scientific reports Medium 28186199
2015 EGF receptor activation triggers ERK1/2-mediated threonine phosphorylation of Kv1.3, causing clathrin-dependent endocytosis and lysosomal degradation of the channel. PDZ and SH3 interaction motifs and tyrosine residues are not required for this mechanism; the ERK1/2-mediated threonine phosphorylation is the critical step. Endocytosis assays, clathrin inhibitors, site-directed mutants (PDZ, SH3, tyrosine residues), ERK inhibitors, confocal microscopy Cellular and molecular life sciences Medium 26542799
2016 Kv1.3 is targeted to caveolar lipid raft microdomains through a highly hydrophobic caveolin-binding domain (FQRQVWLLF) in the intracellular N-terminus that interacts with caveolin-1. Mutations or associations altering this domain impair caveolin recognition and change channel surface localization. Co-immunoprecipitation, co-localization, mutagenesis of caveolin-binding domain, cholesterol depletion, lipid raft fractionation Scientific reports Medium 26931497
2021 Disruption of the Kv1.3–caveolin-1 interaction (via a caveolin-binding domain mutant) causes Kv1.3 to accumulate in mitochondria rather than the plasma membrane, severely affecting mitochondrial physiology and reducing cell survival, revealing a mitochondrial caveolin-Kv1.3 axis that modulates pro-apoptotic signaling. Caveolin-binding domain mutant expression, subcellular fractionation, mitochondrial physiology assays, cell survival assays in mammalian cells eLife Medium 34196606
2022 Kv1.3 uses the TIM23 complex for translocation to the inner mitochondrial membrane via an unconventional mechanism (no defined N-terminal presequence; transmembrane domains cooperatively mediate targeting). The cytosolic HSP70/HSP90 chaperone complex is a key regulator of the mitochondrial import process. Mitochondrial import assays, TIM23 complex interaction studies, HSP70/HSP90 inhibition, subcellular fractionation, domain-deletion constructs Frontiers in oncology Medium 35402277
2012 N-glycosylation of Kv1.3 at position N229 in the S1-S2 extracellular linker promotes cell surface expression; blocking N-glycosylation reduces surface protein levels by ~49% and surface conductance by ~46%. GlcNAc supplementation increases surface Kv1.3 half-life by decreasing internalization. N-glycosylation site mutagenesis, surface biotinylation, patch clamp, monosaccharide supplementation experiments The FEBS journal Medium 22613618
2008 Kv1.3 and Kv1.5 form heterotetramers in macrophages that differ in surface localization compared to Kv1.3 homotetramers; Kv1.5 association modifies Kv1.3 trafficking and reduces its caveolin-associated raft targeting. FRAP analysis shows higher lateral mobility for Kv1.3/Kv1.5 heteromers than Kv1.3 homotetramers. FRET, co-immunoprecipitation, FRAP, cholesterol depletion, caveolae co-localization, confocal microscopy in HEK cells and macrophages The Journal of biological chemistry Medium 18218624
2020 The kinase Fyn directly binds to and posttranslationally modifies Kv1.3, modulating its channel activity. Fyn also transcriptionally upregulates Kv1.3 in microglia in response to aggregated α-synuclein. Fyn-dependent regulation of Kv1.3 amplifies neuroinflammatory responses in Parkinson's disease models. Duolink proximity ligation assay, patch-clamp electrophysiology, Kv1.3-KO primary microglia, PAP-1 pharmacological inhibition, animal models of PD The Journal of clinical investigation Medium 32597830
1999 In hippocampal microglia, there is a switch from Kv1.5-like current (in non-proliferating cells) to Kv1.3-like current (in proliferating cells) during culture, accompanied by redistribution of Kv1.5 protein away from and Kv1.3 protein to the cell surface. Pharmacological inhibition correlated with the Kv channel type expressed indicates that Kv1.3 current is required for microglial proliferation. Tissue printing from brain slices, whole-cell patch clamp, immunocytochemistry, K+ channel blockers, proliferation assays The Journal of neuroscience Medium 10594052
2005 Kv1.3 channel activity in activated microglia is required for microglial-mediated neurotoxicity toward hippocampal neurons. The neurotoxic mechanism involves peroxynitrite production: Kv1.3 blockers reduce the NADPH oxidase-dependent respiratory burst (superoxide), without affecting nitric oxide production, thereby limiting peroxynitrite formation. Kv1.3 channel activity in this pathway is distinct from p38 MAPK used by minocycline. Transwell co-culture, LPS/phorbol ester activation, Kv1.3 channel blockers, reactive oxygen species measurement, NO measurement, p38 MAPK inhibitor comparison The Journal of neuroscience Medium 16079396
2021 Kv1.3 channels increase mitochondrial oxidative phosphorylation independently of redox balance, mitochondrial membrane potential, or calcium signaling. This Kv1.3-induced respiration increases ROS production, which drives proliferation. The mechanism requires an intact voltage sensor and C-terminal ERK1/2 phosphorylation site but is channel pore independent (non-conducting mechanism). High-resolution respirometry, selective Kv1.3 channel mutation (poreless, voltage sensor, ERK site), ROS measurement, ROS scavenging, proliferation assays Cell death & disease Medium 33828089
2009 Kv1.3 is present in the inner mitochondrial membrane of lymphocytes and also cancer cells (PC3, MCF-7). Recombinant Kv1.3 pre-incubated with Bax prevents Bax-induced mitochondrial effects, further establishing the Kv1.3-Bax interaction at the mitochondria. Mitochondrial fractionation, Western blot, recombinant protein incubation, mitochondrial functional assays Biochimica et biophysica acta Medium 20114030
2010 Kv1.3 channels contribute to cell-autonomous apoptotic death of retinal ganglion cells after optic nerve transection. siRNA knockdown of Kv1.3 in vivo reduced expression of proapoptotic genes caspase-3, caspase-9, and Bad, distinct from the Kv1.1-depletion effect (which increased antiapoptotic Bcl-XL). In vivo optic nerve transection model, siRNA delivered via cut optic nerve, Kv1.3 blocker injection, qRT-PCR, immunohistochemistry, RGC survival counts Cell death and differentiation Medium 19696788
2009 Kv1.3 premature exit from the immunological synapse in SLE T cells correlates with sustained Ca2+ influx and T cell hyperactivation. In normal T cells, Kv1.3 remains at the IS during termination of Ca2+ influx, suggesting that Kv1.3 trafficking regulates Ca2+ signaling duration. Two-photon microscopy, immunofluorescence, Ca2+ imaging during IS formation in primary T cells from SLE patients vs. controls Cell calcium Medium 19959227
2015 Kv1.3 is expressed in the nuclei of multiple cancer cell lines and human brain tissue. Nuclear Kv1.3 is functional (margatoxin induces nuclear membrane hyperpolarization in a Kv1.3-dependent manner). Nuclear Kv1.3 forms a complex with upstream binding factor 1 (UBF1) and its blockade induces CREB and c-Fos phosphorylation/activation. Sp1 transcription factor binds the Kv1.3 gene promoter and regulates its nuclear expression. Subcellular fractionation, Western blot, nuclear electrophysiology, siRNA knockdown, ChIP assay, co-immunoprecipitation The Journal of biological chemistry Medium 25829491
2020 Kv1.3 channel activity in Th17 cells is required for β1-integrin/VCAM-1-triggered vesicular glutamate release that damages neurons. Blocking Kv1.3 with a specific channel blocker prevents glutamate secretion downstream of β1-integrin signaling. KV1.3 channel blocker (in vitro and intrathecal), glutamate release assays, Ca2+ imaging, SNARE protein identification, VCAM-1 stimulation assays The Journal of clinical investigation Medium 31661467
2003 Kv1.1 and Kv1.3 channels mediate the delayed-rectifying K+ conductance at the apical membrane of rat choroid plexus epithelial cells. 5-HT inhibits this conductance via 5-HT2C receptors activating PKC, which inhibits Kv1.1 and Kv1.3 channels. Whole-cell patch clamp, selective channel blockers (dendrotoxin-K, margatoxin), Western blot, immunocytochemistry, 5-HT2C receptor antagonist, PKC inhibitor American journal of physiology. Cell physiology Medium 14602579
1999 Kv1.3 channels block membrane potential and calcium influx in human T cells. Correolide blocks Kv1.3 channels in T cells, inhibiting anti-CD3-induced calcium elevation, IL-2 production, and T cell proliferation, demonstrating that Kv1.3 controls Ca2+-dependent T cell activation. Electrophysiology, Ca2+ flux assays, cytokine ELISA, proliferation assays, in vivo delayed-type hypersensitivity in miniswine Cellular immunology Medium 10607427
2024 Proximity labeling proteomics (TurboID fused to Kv1.3) in microglia revealed that the N-terminus of Kv1.3 is responsible for trafficking to cell surface and mitochondria (interactors include NUDC, TIMM50), while the C-terminus interacts with immune signaling proteins (STAT1, TLR2, C3) during LPS-induced inflammation. A C-terminal PDZ-binding domain mediates 70 protein interactions. Kv1.3 functionally couples to STAT1 interferon-mediated signaling (confirmed by channel blockade). TurboID proximity labeling, mass spectrometry, electrophysiology, Western blot, flow cytometry, domain-specific constructs Molecular & cellular proteomics Medium 38936775
2018 Kv1.3 is localized to caveolae in adipocytes via interaction with caveolin-1. Insulin-dependent phosphorylation of Kv1.3 occurs during insulin signaling. In caveolin-1-deficient adipocytes, Kv1.3 is displaced from caveolar rafts and shows impaired insulin-dependent phosphorylation, indicating caveolar targeting is required for proper insulin signaling through Kv1.3. Caveolin-1 KO adipocyte cell line, lipid raft fractionation, co-immunoprecipitation, phosphorylation assays, glucose uptake assays Cellular and molecular life sciences Medium 29947924
2016 Kv1.3 channel activity contributes to both NADPH oxidase-dependent ROS production and proliferation in M1-like microglia. Both Kv1.3 and KCa3.1 blockers inhibit pro-inflammatory cytokine production and iNOS/COX2 expression in LPS/IFN-γ-activated (M1) microglia. Whole-cell patch clamp, quantitative PCR, immunohistochemistry, pharmacological blockers (PAP-1, ShK-186, TRAM-34) in mouse neonatal microglia Glia Medium 27696527
1996 Kv1.3 subunit assembly in T lymphocytes is a random process forming tetramers. Once expressed in the plasma membrane, tetramers do not dissociate and reassemble. A truncated Kv1.3 containing only the N-terminus and first two transmembrane segments can suppress endogenous Kv1.3 current by forming non-functional heterotetramers. Kinetic analysis of C-type inactivation of heterotetrameric channels, heterologous expression in Jurkat cells, dominant-negative suppression assays The Journal of general physiology Medium 8868051
2008 Kv1.3 channels are expressed in postganglionic sympathetic neurons at cell bodies, processes, and sympathetic neurovascular junctions. Margatoxin-sensitive Kv1.3 current depolarizes resting membrane potential and decreases action potential latency. Kv1.3 modulates nicotinic ACh receptor-induced norepinephrine release; muscarinic receptor activation with bethanechol suppresses Kv1.3 current. RT-PCR, immunoblot, immunohistochemistry, whole-cell patch clamp, margatoxin pharmacology, norepinephrine release assay American journal of physiology. Regulatory, integrative and comparative physiology Medium 18614767

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1989 Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. The Journal of biological chemistry 507 2732228
2006 Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America 465 17088564
2008 Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 193 18818304
2005 Microglia Kv1.3 channels contribute to their ability to kill neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience 171 16079396
2004 Kv1.3 channel gene-targeted deletion produces "Super-Smeller Mice" with altered glomeruli, interacting scaffolding proteins, and biophysics. Neuron 148 14766178
2016 Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia. Glia 134 27696527
1999 A Kv1.5 to Kv1.3 switch in endogenous hippocampal microglia and a role in proliferation. The Journal of neuroscience : the official journal of the Society for Neuroscience 133 10594052
2006 Association of Kv1.5 and Kv1.3 contributes to the major voltage-dependent K+ channel in macrophages. The Journal of biological chemistry 131 17038323
2004 Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Molecular pharmacology 120 15155830
2013 The voltage-dependent K(+) channels Kv1.3 and Kv1.5 in human cancer. Frontiers in physiology 118 24133455
2020 Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease. The Journal of clinical investigation 108 32597830
2015 Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease. Journal of Alzheimer's disease : JAD 106 25362031
1997 Modulation of the Kv1.3 potassium channel by receptor tyrosine kinases. The Journal of general physiology 101 9348331
2018 Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept. Brain : a journal of neurology 100 29272333
2011 The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression. Drug development research 99 22241939
2003 Expression of voltage-gated potassium channels Kv1.3 and Kv1.5 in human gliomas. Neuroscience letters 97 12850541
2017 Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions. Nature communications 94 28248292
2009 Kv1.3 potassium channels as a therapeutic target in multiple sclerosis. Expert opinion on therapeutic targets 89 19538097
2017 The secret life of ion channels: Kv1.3 potassium channels and proliferation. American journal of physiology. Cell physiology 83 28931540
2006 The potassium channels Kv1.5 and Kv1.3 modulate distinct functions of microglia. Molecular and cellular neurosciences 82 17055293
2022 Structures of the T cell potassium channel Kv1.3 with immunoglobulin modulators. Nature communications 80 35788586
2015 The voltage-gated potassium channel Kv1.3 is a promising multitherapeutic target against human pathologies. Expert opinion on therapeutic targets 78 26634786
2007 Minocycline decreases in vitro microglial motility, beta1-integrin, and Kv1.3 channel expression. Journal of neurochemistry 78 17868321
1999 Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cellular immunology 78 10607427
2019 Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer. Frontiers in oncology 77 31612103
2009 Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human cancer. Current cancer drug targets 75 20025600
2003 Compensatory anion currents in Kv1.3 channel-deficient thymocytes. The Journal of biological chemistry 75 12878608
2010 Role of Kv1.3 mitochondrial potassium channel in apoptotic signalling in lymphocytes. Biochimica et biophysica acta 74 20114030
2012 Kv1.3 channels can modulate cell proliferation during phenotypic switch by an ion-flux independent mechanism. Arteriosclerosis, thrombosis, and vascular biology 73 22383699
2013 Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 72 23729813
2014 A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases. Scientific reports 71 24676092
2013 Blockade of Kv1.3 channels ameliorates radiation-induced brain injury. Neuro-oncology 68 24305723
2009 KCNE4 suppresses Kv1.3 currents by modulating trafficking, surface expression and channel gating. Journal of cell science 68 19773357
2003 KCNE4 is an inhibitory subunit to Kv1.1 and Kv1.3 potassium channels. Biophysical journal 66 12944270
2006 Kv1.3/Kv1.5 heteromeric channels compromise pharmacological responses in macrophages. Biochemical and biophysical research communications 62 17157812
2020 Kv1.3 channel blockade alleviates cerebral ischemia/reperfusion injury by reshaping M1/M2 phenotypes and compromising the activation of NLRP3 inflammasome in microglia. Experimental neurology 61 32652099
2008 Kv1.5 association modifies Kv1.3 traffic and membrane localization. The Journal of biological chemistry 61 18218624
2000 Transmembrane biogenesis of Kv1.3. Biochemistry 60 10651649
2012 Induction of apoptosis in macrophages via Kv1.3 and Kv1.5 potassium channels. Current medicinal chemistry 59 22856664
2012 Targeting the voltage-dependent K(+) channels Kv1.3 and Kv1.5 as tumor biomarkers for cancer detection and prevention. Current medicinal chemistry 55 22204339
2007 Reduced Kv1.3 potassium channel expression in human prostate cancer. The Journal of membrane biology 54 17546508
2006 Selective blockage of Kv1.3 and Kv3.1 channels increases neural progenitor cell proliferation. Journal of neurochemistry 54 17029597
1997 Native Kv1.3 channels are upregulated by protein kinase C. The Journal of membrane biology 54 9070466
2015 Molecular Determinants of Kv1.3 Potassium Channels-induced Proliferation. The Journal of biological chemistry 51 26655221
2010 Kv1.1 and Kv1.3 channels contribute to the degeneration of retinal ganglion cells after optic nerve transection in vivo. Cell death and differentiation 51 19696788
2017 Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke. Annals of clinical and translational neurology 50 29468176
2014 Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. Journal of Crohn's & colitis 50 24793818
2016 Kv1.3 Channels Mark Functionally Competent CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer. Cancer research 49 27815390
2015 Nuclear localization and functional characteristics of voltage-gated potassium channel Kv1.3. The Journal of biological chemistry 46 25829491
2009 Predominant functional expression of Kv1.3 by activated microglia of the hippocampus after Status epilepticus. PloS one 46 19707551
2020 β1-Integrin- and KV1.3 channel-dependent signaling stimulates glutamate release from Th17 cells. The Journal of clinical investigation 45 31661467
2017 Targeting the Potassium Channel Kv1.3 Kills Glioblastoma Cells. Neuro-Signals 45 28869943
2015 Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune Diseases. Toxins 45 25996605
2011 KCNE2 forms potassium channels with KCNA3 and KCNQ1 in the choroid plexus epithelium. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 43 21859894
2015 Voltage-Gated Potassium Channels Kv1.3--Potentially New Molecular Target in Cancer Diagnostics and Therapy. Advances in clinical and experimental medicine : official organ Wroclaw Medical University 42 26467143
2012 Involvement of Kv1.3 and p38 MAPK signaling in HIV-1 glycoprotein 120-induced microglia neurotoxicity. Cell death & disease 42 22258405
2016 Epigenetic regulation of Kcna3-encoding Kv1.3 potassium channel by cereblon contributes to regulation of CD4+ T-cell activation. Proceedings of the National Academy of Sciences of the United States of America 40 27439875
2021 Unique molecular characteristics and microglial origin of Kv1.3 channel-positive brain myeloid cells in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 39 33649184
2015 Biophysical characterization and expression analysis of Kv1.3 potassium channel in primary human leukemic B cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 38 26393354
2014 Kv1.3 channels modulate human vascular smooth muscle cells proliferation independently of mTOR signaling pathway. Pflugers Archiv : European journal of physiology 38 25208915
2003 Kv1.1 and Kv1.3 channels contribute to the delayed-rectifying K+ conductance in rat choroid plexus epithelial cells. American journal of physiology. Cell physiology 38 14602579
2022 The voltage-gated potassium channel KV1.3 regulates neutrophil recruitment during inflammation. Cardiovascular research 37 33881519
2016 Caveolin interaction governs Kv1.3 lipid raft targeting. Scientific reports 37 26931497
2011 Polymorphism in the KCNA3 gene is associated with susceptibility to autoimmune pancreatitis in the Japanese population. Disease markers 37 22045429
2014 Acacetin blocks kv1.3 channels and inhibits human T cell activation. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 33 25301362
2009 Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus. Cell calcium 32 19959227
1997 Regulation of native Kv1.3 channels by cAMP-dependent protein phosphorylation. The American journal of physiology 32 9277360
2016 Kv1.3 potassium channel mediates macrophage migration in atherosclerosis by regulating ERK activity. Archives of biochemistry and biophysics 31 26748289
1998 Functional expression of GFP-tagged Kv1.3 and Kv1.4 channels in HEK 293 cells. The European journal of neuroscience 29 9875368
2022 Blockade of Kv1.3 Potassium Channel Inhibits Microglia-Mediated Neuroinflammation in Epilepsy. International journal of molecular sciences 28 36499018
2012 N-glycosylation promotes the cell surface expression of Kv1.3 potassium channels. The FEBS journal 27 22613618
2021 Kv1.3 voltage-gated potassium channels link cellular respiration to proliferation through a non-conducting mechanism. Cell death & disease 26 33828089
2018 Alleviating airway inflammation by inhibiting ERK-NF-κB signaling pathway by blocking Kv1.3 channels. International immunopharmacology 26 30077824
2014 Physiological significance of delayed rectifier K(+) channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease. The journal of physiological sciences : JPS 26 25096892
1996 Assembly and suppression of endogenous Kv1.3 channels in human T cells. The Journal of general physiology 26 8868051
2013 Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment? Pharmacotherapy 24 23649812
2024 Proximity Labeling Proteomics Reveals Kv1.3 Potassium Channel Immune Interactors in Microglia. Molecular & cellular proteomics : MCP 23 38936775
2022 Spinal voltage-gated potassium channel Kv1.3 contributes to neuropathic pain via the promotion of microglial M1 polarization and activation of the NLRP3 inflammasome. European journal of pain (London, England) 23 36440534
2021 IL-17 Inhibits Oligodendrocyte Progenitor Cell Proliferation and Differentiation by Increasing K+ Channel Kv1.3. Frontiers in cellular neuroscience 23 34239419
2019 Temporal profiling of Kv1.3 channel expression in brain mononuclear phagocytes following ischemic stroke. Journal of neuroinflammation 23 31153377
2018 A Kv1.3 channel-specific blocker alleviates neurological impairment through inhibiting T-cell activation in experimental autoimmune encephalomyelitis. CNS neuroscience & therapeutics 23 29577640
2017 Ubiquitination mediates Kv1.3 endocytosis as a mechanism for protein kinase C-dependent modulation. Scientific reports 23 28186199
2022 The Mitochondrial Routing of the Kv1.3 Channel. Frontiers in oncology 22 35402277
2021 A novel mitochondrial Kv1.3-caveolin axis controls cell survival and apoptosis. eLife 22 34196606
2018 A novel PADRE-Kv1.3 vaccine effectively induces therapeutic antibodies and ameliorates experimental autoimmune encephalomyelitis in rats. Clinical immunology (Orlando, Fla.) 22 29496642
2018 Kv1.3 activity perturbs the homeostatic properties of astrocytes in glioma. Scientific reports 22 29769580
2016 The C-terminal domain of Kv1.3 regulates functional interactions with the KCNE4 subunit. Journal of cell science 22 27802162
2014 The role of T cell potassium channels, KV1.3 and KCa3.1, in the inflammatory cascade in ulcerative colitis. Danish medical journal 22 25370966
2022 Kv1.3 Channel Is Involved In Ox-LDL-induced Macrophage Inflammation Via ERK/NF-κB signaling pathway. Archives of biochemistry and biophysics 21 36100082
2021 The Kv1.3 K+ channel in the immune system and its "precision pharmacology" using peptide toxins. Biologia futura 21 34554500
2018 Voltage Gated Potassium Channel Kv1.3 Is Upregulated on Activated Astrocytes in Experimental Autoimmune Encephalomyelitis. Neurochemical research 21 29574670
2015 Unconventional EGF-induced ERK1/2-mediated Kv1.3 endocytosis. Cellular and molecular life sciences : CMLS 20 26542799
2008 Kv1.3 channels in postganglionic sympathetic neurons: expression, function, and modulation. American journal of physiology. Regulatory, integrative and comparative physiology 20 18614767
2005 Kv1.3 potassium channel blockade as an approach to insulin resistance. Expert opinion on therapeutic targets 20 15948674
2022 Pharmacological blockade of KV1.3 channel as a promising treatment in autoimmune diseases. Journal of translational autoimmunity 19 35146402
2020 Kv1.3 blockade inhibits proliferation of vascular smooth muscle cells in vitro and intimal hyperplasia in vivo. Translational research : the journal of laboratory and clinical medicine 19 32522668
2019 Mitochondrial Kv1.3: a New Target in Cancer Biology? Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 19 31854954
2018 Caveolar targeting links Kv1.3 with the insulin-dependent adipocyte physiology. Cellular and molecular life sciences : CMLS 19 29947924
2013 Expression of Kv1.3 potassium channels regulates density of cortical interneurons. Developmental neurobiology 19 23821603
2022 Kv1.3 K+ Channel Physiology Assessed by Genetic and Pharmacological Modulation. Physiology (Bethesda, Md.) 18 35998249

Missed literature

Know a paper Affinage missed for KCNA3? Flag it for the maintainers and the community.

No submissions yet.